Egis Pharmaceuticals PLC inaugurates new active ingredient manufacturing plant
Egis Pharmaceuticals PLC has inaugarated one of the largest active pharmaceutical ingredient (API) investments in its 112-year history in Budapest. The new HUF 30 billion plant, financed from the company’s own resources, will produce the active ingredient of a globally market-leading medicine, featuring numerous technological innovations.